Back

Genetic testing in presumed cardiac sarcoidosis

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Arrhythmogenic cardiomyopathy and cardiac sarcoidosis Diagnostic Methods ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Matteo Castrichini

Cattinara e Maggiore di Trieste Hospital, Trieste (Italy)

6 More presentations in this session

Presentation thumbnail
Correlation between epsilon wave and late potentials in arrythmogenic right ventricular cardiomyopathy. Do late potentials define the epsilon wave?
Doctor U. Skrzypczynska-Banasik (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Influence of left ventricular ejection fraction, type of mutation and sex on malignant ventricular arrhythmias in dsp and flnc mutations
Doctor A. Perez Ferrandiz (Sant Joan d'Alacant, ES)
Abstract Slides Video
Presentation thumbnail
Arrhythmic risk stratification in patients with left ventricular ring-like scar
Doctor V. Parisi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of family screening in Dilated and Arrhythmogenic Cardiomyopathies
Miss E. Del Mestre (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Arrhythmogenic cardiomyopathy phenotype associated with the pathogenic founder variant c.1211dup in PKP2
Mr T. Bos (Leiden, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmogenic cardiomyopathy and cardiac sarcoidosis

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Predictive factors for genetic positive test in genetic myocarditis
thumbnail
Congress Presentation
Genetic testing in inflammatory cardiomyopathy/myocarditis: a red flag for cardiomyopathy-like histologic findings
thumbnail
Congress Presentation
Challenges in the diagnosis of cardiac sarcoidosis- an observational study from northern India

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources